ILO Home
Volver a la página de entrada
Site map | Contact us English | Français

Base de datos CISDOC

ID (ISN) del documento52020
Número CIS 89-1258
ISSN - Título de la serie 0002-8894 - American Industrial Hygiene Association Journal
Año 1988
Número de serie
Autor(es) Pyy L., Sorsa M., Hakala E.
Título Ambient monitoring of cyclophosphamide in manufacture and hospitals
Información bibliográfica June 1988, Vol.49, No.6, p.314-317. Illus. 6 ref.
Resumen Cyclophosphamide (CP), one of the most commonly used cytostatic drugs, is a human carcinogen. In this study, CP was a model compound for the identification of potential exposure situations in the various phases of its manufacture and hospital use. Ambient air samples were taken in the various phases and analysed for CP. A low detection limit (0.05µg/m3 for a 1m3 sample volume) was obtained for CP by the mass spectrometric method developed for this study. The detection limit was 1µg/m3 with high performance liquid chromatography. The correlation between the 2 methods was good. The highest potential exposure situations were found during specific operations at the end of the manufacturing process. During these operations the airborne CP concentrations may rise as high as several hundred µg/m3, and the workers must use supplied air respirators, gloves and protective clothing. For the measurements in hospital use, air samples were taken from flow hoods. During normal working practices, no measurable amounts of CP could be observed. A filter from a flow hood, however, contained CP in measurable quantities, showing that occasional spilling may occur.
Descriptores (primarios) ciclofosfamida; valoración de la exposición; industria farmacéutica; toma de muestras y análisis; hospitales
Descriptores (secundarios) substancias cancerígenas; descripción del procedimiento; toma de muestras del aire; citostáticos
Tipo de documento D - Artículos periódicos
Tema(s) Sustancias tóxicas y peligrosas
Broad subject area(s) Riesgos químicos
Navegación por categoria(s) Exposure evaluation
Heterocyclic compounds
Health care services
Pharmaceutical industry